

Drug Monograph

Drug Name: **AirDuo[®] Digihaler[™] (fluticasone propionate/salmeterol) Inhalation Powder**

Drug Class: **Inhaled Corticosteroid, Long Acting Beta Agonist**

Prepared For: MO HealthNet

Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	AirDuo Digihaler contains fluticasone propionate in combination with salmeterol in the following strengths: 55 mcg/14 mcg, 113 mcg/14 mcg, 232 mcg/14 mcg. The AirDuo product now contains the Digihaler component which is a built-in electronic module which detects, records, and stores data on inhaler events for transmission to mobile app.	
Manufacturer:	Teva Respiratory, LLC., Frazer, PA 19355.	
Indications:	AirDuo Digihaler is indicated for the treatment of asthma in patients aged 12 years and older. AirDuo Digihaler should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta ₂ adrenergic agonist (LABA).	
Costs:	\$400 per inhaler (55mcg/14mcg, 113mcg/14mcg products); \$450 per inhaler (232mcg/14mcg product) Wholesale Acquisition Cost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred	
Status Recommendation:	<input type="checkbox"/> Clinical Edit <input type="checkbox"/> Open Access	<input type="checkbox"/> PA Required <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required	<input checked="" type="checkbox"/> Non-Preferred <input type="checkbox"/> Preferred

Prepared by: Megan Fast, PharmD.
Date: September 30, 2020

